Drug Trial Radar · NCT02558829
Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency
Last checked: Nov 20, 2026Latest source record: Apr 10, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
157
Actual
Start
Dec 3, 2015
Primary completion
Nov 29, 2016
Study completion Nov 29, 2016
Sponsor
- Lead sponsor
- AEterna ZentarisIndustry
- Sponsor type
- Industry
- First posted
- Sep 24, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The Macimorelin Growth Hormone Stimulation Test (GHST) will be compared with the Insulin Tolerance Test (ITT) in an open-label, randomized, 2-way crossover Trial. The trial will include subjects suspected to have adult growth hormone deficiency (AGHD) and a group of healthy control subjects.
Conditions
- Growth Hormone Deficiency With Pituitary Anomalies
Interventions
MacimorelinDrug
macimorelin acetate, 0.5 mg/kg body weight, drinking solution, single dose
InsulinDrug
Insulin, 0.10 U/kg (0.15 U/kg if BMI \> 30 kg/m2), intravenous injection, single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Co-primary Efficacy Variables: Percent Positive and Percent Negative Agreement of Macimorelin-GHST (MAC) With ITTTime frame: 90 minutes
Locations
27 sites in 9 countries. Site status is shown where the registry gives one.
Harbor UCLA Medical Center
Torrance, California
Texas Diabetes and Endocrinology
Austin, Texas
Baylor College of Medicine-Endocrinology
Houston, Texas
VA Puget Sound Health Care System
Seattle, Washington
Swedish Medical Center - Cherry Hill
Seattle, Washington
Krankenanstalt Rudolfstiftung
Vienna, Austria
Medical University & General Hospital of Vienna, AKH,
Vienna, Austria
CHU de Lyon HCL-GH Est
Bron, France
GHU Paris-Sud - Hôpital de Bicêtre
Le Kremlin-Bicêtre, France
Hôpital Haut-Lévêque
Pessac, France
Klinik für Endokrinologie, Diabetes und Ernährungsmedizin der Charité
Berlin, Germany
Klinikum der LMU München
Munich, Bavaria, Germany
Max Planck Institut
Munich, Bavaria, Germany
University Hospital Marburg
Marburg, Hesse, Germany
RWTH Aachen University Hospital
Aachen, North Rhine-Westphalia, Germany
San Luca Hospital
Milan, Italy
Centrum Kliniczno-Badawcze
Elblag, Poland
Centrum Medyczne Angelius Provita
Katowice, Poland
Phase I - MTZ Clinical Research Sp. z o.o.
Warsaw, Poland
Wromedica
Wroclaw, Poland
Clinical Centre of Serbia
Belgrade, Serbia
Clinical Centre of Vojvodina
Novi Sad, Serbia
Hospital de Sant Pau
Barcelona, Spain
Hospital Universitari Vall d' Hebron
Barcelona, Spain
Hospital de Conxo
Santiago de Compostela, Spain
St Bartholomew's Hospital
London, United Kingdom
The Christie NHS Foundation Trust
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.